Home Cart 0 Sign in  
X

[ CAS No. 139102-34-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 139102-34-4
Chemical Structure| 139102-34-4
Chemical Structure| 139102-34-4
Structure of 139102-34-4 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 139102-34-4 ]

Related Doc. of [ 139102-34-4 ]

Alternatived Products of [ 139102-34-4 ]

Product Details of [ 139102-34-4 ]

CAS No. :139102-34-4 MDL No. :MFCD06797867
Formula : C9H9BrO3 Boiling Point : -
Linear Structure Formula :- InChI Key :WPGAGRPPDYAZAD-UHFFFAOYSA-N
M.W : 245.07 Pubchem ID :15128242
Synonyms :

Calculated chemistry of [ 139102-34-4 ]

Physicochemical Properties

Num. heavy atoms : 13
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.22
Num. rotatable bonds : 3
Num. H-bond acceptors : 3.0
Num. H-bond donors : 0.0
Molar Refractivity : 51.91
TPSA : 35.53 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.86 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.48
Log Po/w (XLOGP3) : 2.73
Log Po/w (WLOGP) : 2.24
Log Po/w (MLOGP) : 2.36
Log Po/w (SILICOS-IT) : 2.39
Consensus Log Po/w : 2.44

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.22
Solubility : 0.147 mg/ml ; 0.000599 mol/l
Class : Soluble
Log S (Ali) : -3.13
Solubility : 0.182 mg/ml ; 0.000741 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.46
Solubility : 0.085 mg/ml ; 0.000347 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.68

Safety of [ 139102-34-4 ]

Signal Word:Warning Class:
Precautionary Statements:P280-P305+P351+P338 UN#:
Hazard Statements:H317-H319 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 139102-34-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 139102-34-4 ]
  • Downstream synthetic route of [ 139102-34-4 ]

[ 139102-34-4 ] Synthesis Path-Upstream   1~13

  • 1
  • [ 139102-34-4 ]
  • [ 17102-63-5 ]
YieldReaction ConditionsOperation in experiment
94% With lithium borohydride In tetrahydrofuran at 60℃; for 16 h; Inert atmosphere To a solution of methyl 4-bromo-2-methoxybenzoate (7.14g, 29mmol) in THF (35mL) was added a 2M solution of LiBH4 in THF (35mL, 70mmol, 2.4equiv). The solution was heated at 60°C for 16h. The reaction was then cooled to room temperature, and the solvent was removed under vacuum. The residue was stirred in a 5percent aqueous acetic acid solution (pH 6) for 15min. The aqueous layer was extracted with EtOAc (2×50mL), then the combined organic extracts were washed with brine, dried (MgSO4), filtered, and concentrated to yield the crude product as a tan oil. The oil was purified by flash chromatography using 5percent EtOAc in hexanes to provide 5.96g (94percent) of the product as a white solid: Rf 0.30 (10percent EtOAc/hexane); 1H NMR (CDCl3) δ 7.30 (d, 1H), 7.14 (d, 1H), 7.11 (s, 1H), 5.09 (t, 1H), 4.42 (d, 2H,), 3.77 (s, 3H).
Reference: [1] Bioorganic and Medicinal Chemistry, 2014, vol. 22, # 1, p. 419 - 434
[2] Journal of Medicinal Chemistry, 1992, vol. 35, # 4, p. 734 - 740
[3] Patent: WO2006/60461, 2006, A1, . Location in patent: Page/Page column 197
[4] ChemMedChem, 2010, vol. 5, # 1, p. 65 - 78
[5] Patent: WO2012/66335, 2012, A1, . Location in patent: Page/Page column 54
  • 2
  • [ 139102-34-4 ]
  • [ 22717-56-2 ]
YieldReaction ConditionsOperation in experiment
94% With boron tribromide In dichloromethane at 0℃; for 1.83333 h; A 1.0 M solution of boron tribromide (44.0 mL, 44 mmol) in DCM (20 mL) was cooled to 0C. Then, a solution of compound D (17.4 mmol) in DCM (120 mL) was slowly added over during 20 minutes. The reaction mixture was vigorously stirred for 1.5h at 0C. Water was added and the organic phase was separated. The aqueous phase was extracted with DCM and EtOAc. The combined organic phases were dried (MgSO4) and evaporated under reduced pressure to give a white powder. The crude solid was purified by flash chromatography (hexane:ethylacetate 9:1) to give the desired product E (yield 94percent).
Reference: [1] European Journal of Organic Chemistry, 2017, vol. 2017, # 22, p. 3288 - 3300
[2] Tetrahedron, 2015, vol. 71, # 26-27, p. 4535 - 4542
  • 3
  • [ 1666-28-0 ]
  • [ 74-88-4 ]
  • [ 139102-34-4 ]
YieldReaction ConditionsOperation in experiment
85% With potassium carbonate In acetoneHeating / reflux 4-Bromo-2-hydroxybenzoic acid (1.00 g, 4.61 mmol) was dissolved in acetone (25 mL), and iodomethane (1.15 mL, 18.4 mmol) and K2CO3 (2.55 g, 18.4 mmol) were added. The reaction was heated at reflux overnight. Upon cooling to rt, the reaction mixture was filtered, and the filtrate was concentrated in vacuo. The crude material was purified by flash chromatography (Biotage.(R). column; 10percent EtOAc / Hexanes), yielding 0.955 g (85percent) of the desired product as a yellow oil. LC/MS m/z 245.0 (MH+); retention time 3.13 min. 1H NMR (400 MHz, CD2Cl2) δ 3.84 (s, 3H), 3.90 (s, 3H), 7.12-7.20 (m, 2H), 7.62 (d, IH).
Reference: [1] Journal of Medicinal Chemistry, 1992, vol. 35, # 4, p. 734 - 740
[2] Patent: WO2006/44775, 2006, A2, . Location in patent: Page/Page column 17
[3] Patent: EP1445249, 2004, A1, . Location in patent: Page 138
  • 4
  • [ 1666-28-0 ]
  • [ 77-78-1 ]
  • [ 139102-34-4 ]
YieldReaction ConditionsOperation in experiment
96.4%
Stage #1: With potassium carbonate In acetone for 1 h; Reflux; Large scale
Stage #2: for 6.5 h; Reflux; Large scale
3.06 kg (22.12 mol) of potassium carbonate were initially charged in 3.6 1 of acetone and heated to reflux. To this suspension were added 1.2 kg of 4-bromo-2-hydroxy- benzoic acid (5.53 mol), suspended in 7.8 1 of acetone, and were rinsed in with 0.6 1 of acetone. The suspension was heated under reflux for 1 hour (vigorous evolution of gas).2.65 kg (21.01 mol) of dimethyl sulphate were then added over 4 hours while boiling. The mixture was subsequently stirred under reflux for 2.5 hours. The solvent was largely distilled oil (to the point of stirrability) and 12 1 of toluene were added and the residual acetone was then distilled off at 110° C. About 3 1 of distillate were distilled off, this being supplemented by addition of a further 3 1 of toluene to the mixture. The mixture was allowed to cool to 20° C. and 10.8of water were added and vigorously stirred in. The organic phase was separated off and the aqueous phase was extracted once more with 6.1 1 of toluene. The combined organic phases were washed with 3 1 of saturated sodium chloride solution and the toluene phase is concentrated to about 4 1. Determination of the content by evaporation of a portion resulted in a converted yield of 1.306 kg (96.4percent of theory). The solution was used directly in the subsequent stage. HPLC method A: RT about 11.9 mm. MS (Elpos): mlz=245 [M+H] ‘H NMR (400 MHz, CD2C12): ö=3.84 (s, 3H), 3.90 (s, 3H), 7.12-7.20 (m, 2H), 7.62 (d, 1H).
96.4%
Stage #1: With potassium carbonate In acetone for 1 h; Reflux; Large scale
Stage #2: for 6.5 h; Reflux; Large scale
3.06 kg (22.12 mol) of potassium carbonate were initially charged in 3.6 1 of acetone and heated to reflux. To this suspension were added 1.2 kg of 4-bromo-2-hydroxy- benzoic acid (5.53 mol), suspended in 7.8 1 of acetone, and the latter was rinsed in with 0.6 1 of acetone. The suspension was heated under reflux for 1 hour (vigorous evolution of gas). 2.65 kg (21.01 mol) of dimethyl sulphate were then added over 4 hours while boiling. The mixture was subsequently stirred under reflux for 2.5 hours. The solvent was largely distilled oil (to the point of stirrability) and 12 1 of toluene were added and the residual acetone was then distilled off at 1100 C. About 3 1 of distillate were distilled off, this being supplemented by addition of a further 3 1 of toluene to the mixture. The mixture was allowed to cool to 20° C. and 10.8 1 of water were added and vigorously stirred in. The organic phase was separated off and the aqueous phase was extracted once more with 6.11 of toluene. The combined organic phases were washed with 3 1 of saturated sodium chloride solution and the toluene phase is concentrated to about 4 1. Determination of the content by evaporation of a portion resulted in a converted yield of 1.306 kg (96.4percent of theory). The solution was used directly in the subsequent stage. HPLC-Method A: RT ca. 11,9 mm. MS (Elpos): mlz=245 [M+H] ‘H NMR (400 MHz, CD2C12): ö=3.84 (s, 3H), 3.90 (s, 3H), 7.12-7.20 (m, 2H), 7.62 (d, 1H).
Reference: [1] Patent: US2018/244670, 2018, A1, . Location in patent: Paragraph 0173-0177
[2] Patent: US2018/244668, 2018, A1, . Location in patent: Paragraph 0170; 0171; 0172; 0173
[3] Patent: US2017/217957, 2017, A1, . Location in patent: Paragraph 0139-0142
  • 5
  • [ 22717-56-2 ]
  • [ 74-88-4 ]
  • [ 139102-34-4 ]
Reference: [1] Journal of Medicinal Chemistry, 2012, vol. 55, # 7, p. 3228 - 3241
[2] ChemMedChem, 2010, vol. 5, # 1, p. 65 - 78
  • 6
  • [ 67-56-1 ]
  • [ 72135-36-5 ]
  • [ 139102-34-4 ]
Reference: [1] Patent: WO2017/143011, 2017, A1, . Location in patent: Paragraph 0467-0469
[2] Journal of Medicinal Chemistry, 2018, vol. 61, # 3, p. 666 - 680
  • 7
  • [ 72135-36-5 ]
  • [ 74-88-4 ]
  • [ 139102-34-4 ]
Reference: [1] Journal of Medicinal Chemistry, 2008, vol. 51, # 6, p. 1925 - 1944
  • 8
  • [ 1666-28-0 ]
  • [ 139102-34-4 ]
Reference: [1] Journal of Medicinal Chemistry, 2012, vol. 55, # 7, p. 3228 - 3241
  • 9
  • [ 139102-34-4 ]
  • [ 43192-33-2 ]
YieldReaction ConditionsOperation in experiment
94.1% With 1-methyl-piperazine; sodium bis(2-methoxyethoxy)aluminium dihydride In toluene at -8 - 0℃; for 1.5 h; Large scale 1.936 kg (6.22 mol) of a 65percent Red-Al solution in toluene were charged with 1.25 1 of toluene at -5° C.
To this solution was added 0.66 kg (6.59 mol) of 1-methylpiperazine, which was rinsed in with 150 ml of toluene, keeping the temperature between -7 and -5° C.
The mixture was then left to stir at 0° C. for 30 minutes.
This solution was then added to a solution of 1.261 kg (5.147 mol) of methyl 4-bromo-2-methoxybenzoate (XV), dissolved in 41 of toluene, keeping the temperature at -8 to 0° C.
After rinsing in twice with 0.7 1 of toluene, the mixture was then stirred at 0° C. for 1.5 hours.
For the work-up, the solution was added to cold aqueous sulphuric acid at 0° C. (12.5 1 of water+1.4 kg of conc. sulphuric acid).
The temperature was to increase to a maximum to 10° C. (slow addition).
The pH was adjusted to pH 1, if necessary, by addition of further sulphuric acid.
The organic phase was separated off and the aqueous phase was extracted with 7.6 1 of toluene.
The combined organic phases were washed with 5.1 1 of water and then substantially concentrated and the residue taken up in 10 l of DMF.
The solution was again concentrated to a volume of about 5 l.
Determination of the content by evaporation of a portion resulted in a converted yield of 1.041 kg (94.1percent of theory).
The solution was used directly in the subsequent stage.
HPLC-Method A: RT ca. 12.1 min.
MS (Elpos): m/z=162 [M+H]+
1H-NMR (CDCl3, 400MHz): δ=3.93 (3H, s), 7.17 (2H, m), 7.68 (1H, d), 10.40 (1H, s)
94.1% With 1-methyl-piperazine; sodium bis(2-methoxyethoxy)aluminium dihydride In toluene at -8 - 0℃; for 1.5 h; Large scale 1.936 kg (6.22 mol) of a 65percent Red-Al solution in toluene were charged with 1.25 l of toluene at -5° C.
To this solution was added 0.66 kg (6.59 mol) of 1-methylpiperazine, which was rinsed in with 150 ml of toluene, keeping the temperature between -7 and -5° C.
The mixture was then left to stir at 0° C. for 30 minutes.
This solution was then added to a solution of 1.261 kg (5.147 mol) of methyl 4-bromo-2-methoxybenzoate (XV), dissolved in 4 l of toluene, keeping the temperature at -8 to 0° C.
After rinsing in twice with 0.7 l of toluene, the mixture was then stirred at 0° C. for 1.5 hours.
For the work-up, the solution was added to cold aqueous sulphuric acid at 0° C. (12.5 l of water+1.4 kg of conc. sulphuric acid).
The temperature should increase at maximum to 10° C. (slow addition).
The pH was adjusted to pH 1, if necessary, by addition of further sulphuric acid.
The organic phase was separated off and the aqueous phase was extracted with 7.6 l of toluene.
The combined organic phases were washed with 5.1 l of water and then substantially concentrated and the residue taken up in 10 l of DMF.
The solution was again concentrated to a volume of about 5 l.
Determination of the content by evaporation of a portion resulted in a converted yield of 1.041 kg (94.1percent of theory).
The solution was used directly in the subsequent stage. HPLC method A: RT about 12.1 mm. MS (Elpos): mlz=162 [M+H]. 1H NMR (CDC13, 400MHz): ö=3.93 (3H, s), 7.17 (2H, m), 7.68 (1H, d), 10.40 (1H, s)
Reference: [1] Patent: US2018/244668, 2018, A1, . Location in patent: Paragraph 0174; 0175; 0176; 0177
[2] Patent: US2018/244670, 2018, A1, . Location in patent: Paragraph 0178-0182
[3] Journal of Medicinal Chemistry, 1992, vol. 35, # 4, p. 734 - 740
[4] Bioorganic and Medicinal Chemistry, 2014, vol. 22, # 1, p. 419 - 434
[5] Patent: US2017/217957, 2017, A1, . Location in patent: Paragraph 0143-0146
  • 10
  • [ 139102-34-4 ]
  • [ 72135-36-5 ]
YieldReaction ConditionsOperation in experiment
2.74 g With methanol; lithium hydroxide In water at 20℃; for 3 h; A mixture of Compound I (3.0 g), 2N aqueous lithium hydroxide solution (18 mL) and methanol (55 mL) was stirred at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure, and to the residue was added water, and the mixture was extracted with diisopropylether. The aqueous layer was acidified with 4N hydrochloric acid, and extracted with chloroform. The chloroform layer was dried over magnesium sulfate, and then concentrated under reduced pressure to give Compound II (2.74 g)
Reference: [1] Journal of Medicinal Chemistry, 2013, vol. 56, # 5, p. 1843 - 1852
[2] Patent: EP1445249, 2004, A1, . Location in patent: Page 138
[3] Patent: WO2010/71741, 2010, A1, . Location in patent: Page/Page column 24
[4] Patent: EP2364975, 2011, A1, . Location in patent: Page/Page column 25
[5] Patent: EP2612848, 2013, A1, . Location in patent: Paragraph 0240; 0241; 0242
  • 11
  • [ 139102-34-4 ]
  • [ 21962-45-8 ]
Reference: [1] Patent: US2017/217957, 2017, A1,
[2] Patent: US2018/244668, 2018, A1,
[3] Patent: US2018/244670, 2018, A1,
  • 12
  • [ 139102-34-4 ]
  • [ 330793-38-9 ]
Reference: [1] Patent: WO2008/42925, 2008, A1,
  • 13
  • [ 139102-34-4 ]
  • [ 406719-76-4 ]
Reference: [1] Chemistry - A European Journal, 2013, vol. 19, # 15, p. 4786 - 4797
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 139102-34-4 ]

Aryls

Chemical Structure| 72135-36-5

[ 72135-36-5 ]

4-Bromo-2-methoxybenzoic acid

Similarity: 0.96

Chemical Structure| 260806-90-4

[ 260806-90-4 ]

Methyl 3-bromo-2-methoxybenzoate

Similarity: 0.95

Chemical Structure| 4068-76-2

[ 4068-76-2 ]

Methyl 5-bromo-2-hydroxybenzoate

Similarity: 0.95

Chemical Structure| 134419-43-5

[ 134419-43-5 ]

Methyl 5-bromo-2-hydroxy-3-methoxybenzoate

Similarity: 0.93

Chemical Structure| 62176-31-2

[ 62176-31-2 ]

2-(Benzyloxy)-5-bromobenzoic acid

Similarity: 0.93

Bromides

Chemical Structure| 72135-36-5

[ 72135-36-5 ]

4-Bromo-2-methoxybenzoic acid

Similarity: 0.96

Chemical Structure| 260806-90-4

[ 260806-90-4 ]

Methyl 3-bromo-2-methoxybenzoate

Similarity: 0.95

Chemical Structure| 4068-76-2

[ 4068-76-2 ]

Methyl 5-bromo-2-hydroxybenzoate

Similarity: 0.95

Chemical Structure| 134419-43-5

[ 134419-43-5 ]

Methyl 5-bromo-2-hydroxy-3-methoxybenzoate

Similarity: 0.93

Chemical Structure| 62176-31-2

[ 62176-31-2 ]

2-(Benzyloxy)-5-bromobenzoic acid

Similarity: 0.93

Ethers

Chemical Structure| 72135-36-5

[ 72135-36-5 ]

4-Bromo-2-methoxybenzoic acid

Similarity: 0.96

Chemical Structure| 260806-90-4

[ 260806-90-4 ]

Methyl 3-bromo-2-methoxybenzoate

Similarity: 0.95

Chemical Structure| 134419-43-5

[ 134419-43-5 ]

Methyl 5-bromo-2-hydroxy-3-methoxybenzoate

Similarity: 0.93

Chemical Structure| 62176-31-2

[ 62176-31-2 ]

2-(Benzyloxy)-5-bromobenzoic acid

Similarity: 0.93

Chemical Structure| 17100-65-1

[ 17100-65-1 ]

Methyl 2-bromo-4-methoxybenzoate

Similarity: 0.90

Esters

Chemical Structure| 260806-90-4

[ 260806-90-4 ]

Methyl 3-bromo-2-methoxybenzoate

Similarity: 0.95

Chemical Structure| 4068-76-2

[ 4068-76-2 ]

Methyl 5-bromo-2-hydroxybenzoate

Similarity: 0.95

Chemical Structure| 134419-43-5

[ 134419-43-5 ]

Methyl 5-bromo-2-hydroxy-3-methoxybenzoate

Similarity: 0.93

Chemical Structure| 823225-66-7

[ 823225-66-7 ]

Methyl 8-bromo-2,3-dihydrobenzo[b][1,4]dioxine-5-carboxylate

Similarity: 0.90

Chemical Structure| 39503-57-6

[ 39503-57-6 ]

Methyl 5-bromo-2-hydroxy-4-methylbenzoate

Similarity: 0.90